Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.66 |
| ▸ | CNR1 | P21554 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24728619 | 1.00 | MGLL (0.66) | MGLLCNR1ALDH1A1MAPTTHRB | |
| SCHEMBL24728610 | 1.00 | MGLL (0.66) | MGLLCNR1ALDH1A1MAPTTHRB | |
| SCHEMBL18641682 | 1.00 | MGLL (0.66) | MGLLCNR1ALDH1A1MAPTTHRB | |
| SCHEMBL18641679 | 1.00 | MGLL (0.66) | MGLLCNR1ALDH1A1MAPTTHRB | |
| SCHEMBL20618425 | 1.00 | MGLL (0.66) | MGLLCNR1ALDH1A1MAPTTHRB | |
| SCHEMBL24728782 | 1.00 | MGLL (0.66) | MGLLCNR1ALDH1A1MAPTTHRB | |
| SCHEMBL23940309 | 0.98 | MGLL (0.63) | MGLLCNR1ALDH1A1MAPTTHRB | |
| SCHEMBL22646055 | 0.96 | MGLL (0.62) | MGLLCNR1ALDH1A1MAPTTHRB | |
| SCHEMBL24728761 | 0.96 | MGLL (0.59) | MGLLCNR1ALDH1A1MAPTTHRB | |
| SCHEMBL24728801 | 0.95 | MGLL (0.60) | MGLLCNR1ALDH1A1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242474-A1 | LIPID COMPOUND AND THE COMPOSITION THEREOF | GUANGZHOU RIBOBIO CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242474-A1 | LIPID COMPOUND AND THE COMPOSITION THEREOF | GUANGZHOU RIBOBIO CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| WO-2022112855-A1 | LIPID COMPOUND AND THE COMPOSITION THEREOF | Guangzhou Ribobio Co., Ltd (CN) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242474-A1 | LIPID COMPOUND AND THE COMPOSITION THEREOF | NPC1L1, NPC1, SGMS1 | MGLL 16/4885CNR1 807/4885ALDH1A1 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.